Community post

Armata Pharmaceuticals announces first patient dosed in phase 1b/2a 'diSArm' study of AP-SA02 in adults with bacteremia due to Staphylococcus aureus.

Topics

Source	Capsid & Tail #177

Posted	May 27, 2022

Post ID	capsid-diving-into-a-dao-as-a-scientist-updates-1